[Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].

• DOI: 10.3779/j.issn.1009-3419.2011.09.03
• Publication Date: 2011-09-01
• Authors: Fuhai Li; Hua Bai; Xia’nan Li; Meina Wu; Rong Yu; Anhui Shi; Yin Li; Jie Wang; Guangying Zhu
• Keywords: Chemoradiotherapy

The presence of epidermal growth factor receptor (EGFR) mutations is predictive a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). aim this study analyze the association between outcome combined chemoradiotherapy stage III NSCLC.Patients with NSCLC whose mutation status had been identified were retrospectively analyzed. 87 patients chemoradiotherapy, two-year survival rate, 128 evaluated.The rate was 84.6% (33/39) mutation-positive patients, significantly higher than 56.3% (27/48) mutation-negative (P=0.004). Two-year rates 53.8% 50% respectively. There no significant difference overall for both patient groups. 34.5% (19/55) compared 21.9% (16/73) patients.EGFR can predict but not associated NSCLC.